Hyperalgesia is a medical condition in which a
person develops an increased sensitivity towards pain. There are several nerve
pathways in the body where signals can start miscommunication with each other,
resulting in hyperalgesia.
Request
to Get Free Sample Pages at: https://www.pharmaproff.com/request-sample/1100
Hyperalgesia
can be categorized into several types which includes primary, secondary and
opioid-induced hyperalgesia. The main symptom associated with the disease is
increasing extreme reaction to painful stimuli without any new injury.
Make
Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1100
The disease
can be treated with non-opioid medications, methadone, buprenorphine, and
ketamine. Company like Rottapharm Biotech Srl is in the process of developing
CRB0089 as an anti-TrkA therapeutic monoclonal antibody for the treatment of
hyperalgesia.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment